Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have led to a
substantial improvement in the prognosis of lung cancer patients by explicitly targeting the …

Introduction EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of
lung adenocarcinoma. However, approximately 5% to 10% of patients with lung …

Epidermal growth factor receptor (EGFR) T790M mutation is the most frequent mechanism
which accounts for about 60% of acquired resistance to first-generation EGFR tyrosine …

The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in
human cancer since it contributes to a number of highly relevant processes in tumor …

The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung
cancer (NSCLC) has been shown to be effective in increasing patient progression free …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

NSCLC patients with mutations in epidermal growth factor receptor (EGFR) gene have
dramatic responses with the EGFR tyrosine kinase inhibitors (TKI) in the majority of patients …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …

The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …